A patient with CKD stage 4 has a serum phosphorus of 6.8 mg/dL and is prescribed a calcium-based phosphate binder. What is the primary risk the renal dietitian should monitor for in this scenario?
-
A
Hypocalcemia from binder competition
-
B
Vascular and soft tissue calcification
-
C
Aluminum toxicity from calcium acetate
-
D
Hypomagnesemia from calcium displacement